Savara Pharmaceuticals

Mast Therapeutics, Savara to merge

Monday, January 9, 2017

Mast Therapeutics and Savara, a privately held emerging specialty pharmaceutical company focused on the treatment of rare respiratory diseases, have entered into a definitive merger agreement under which the stockholders of Savara would become the majority owners of Mast, and the operations of Mast and Savara would be combined. Subject to stockholder approval, the combined company will advance a pipeline of novel inhalation therapies for the treatment of diseases with significant unmet medical needs, featuring three product candidates, each in advanced clinical development.  

[Read More]

CFFT grants Savara Pharmaceuticals $1.7 million award

Friday, October 18, 2013

Savara Pharmaceuticals has received a $1.7 million research award from Cystic Fibrosis Foundation Therapeutics(CFFT), the nonprofit drug discovery and development affiliate of the CF Foundation. The award will advance the development of AeroVanc, the first inhaled antibiotic being developed to treat the increasing number of people with cystic fibrosis (CF) who have persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection.

[Read More]